W
WAVEMAN · COMPANY
TNYA · Tenaya Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

TNYA

Tenaya Therapeutics, Inc.
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001858848
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$26.2K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
51
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-3909.3%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$26.2K over 180 days
-$19.9K over 90 days
more than 61% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
51 funds added or opened last quarter
below 55% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
-3909.3% net margin (latest quarter)
below 96% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$26.2K across 3 people in 180 days.
51 funds added or opened positions in the latest 13F quarter, of 103 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -36.8%
-36.8%12M
-49%-1%+47%+94%2025-092025-102025-122026-032026-052026-072026-09 2026-02-11 · COLUMN GROUP III-A, LP sold $1.5M2026-02-11 · COLUMN GROUP III-A, LP sold $1.3M2026-02-25 · TCG Opportunity III GP, LLC sold $1.0M2026-02-25 · TCG Opportunity III GP, LLC sold $923.6K2026-02-24 · TCG Opportunity III GP, LLC sold $216.5K2026-02-24 · TCG Opportunity III GP, LLC sold $191.7K2026-02-20 · COLUMN GROUP III-A, LP sold $169.4K2026-02-20 · COLUMN GROUP III-A, LP sold $150.0K2026-02-10 · COLUMN GROUP III-A, LP sold $149.5K2026-02-10 · COLUMN GROUP III-A, LP sold $132.4K2026-02-23 · COLUMN GROUP III-A, LP sold $97.4K2026-02-23 · COLUMN GROUP III-A, LP sold $86.2K2026-08-17 · Ali Faraz sold $5.3K2025-11-17 · Ali Faraz sold $4.2K2026-08-17 · Ali Faraz sold $4.1K2025-11-17 · Tingley Whittemore sold $3.8K2026-02-17 · Ali Faraz sold $3.7K2026-08-17 · Ali Faraz sold $3.6K2026-02-17 · Ali Faraz sold $3.2K2026-08-17 · Ali Faraz sold $2.8K2026-05-18 · Ali Faraz sold $2.7K2026-02-17 · Ali Faraz sold $2.5K2026-05-18 · Tingley Whittemore sold $2.5K2025-11-17 · Higa Tomohiro sold $1.8K2026-08-17 · Tingley Whittemore sold $1.6K2026-08-17 · Tingley Whittemore sold $1.3K2026-02-17 · Higa Tomohiro sold $1.3K2026-02-17 · Tingley Whittemore sold $1.2K2026-05-18 · Higa Tomohiro sold $1.2K2026-08-17 · Tingley Whittemore sold $1.2K2026-02-17 · Tingley Whittemore sold $1.1K2026-02-17 · Higa Tomohiro sold $5352026-02-17 · Higa Tomohiro sold $3912026-08-17 · Faraz Ali filed to sell $15.8K2026-08-17 · Whittemore Tingley filed to sell $5.3K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $26.2K sold by insiders over 180 days, 51 funds added last quarter, $21.0K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Tenaya Therapeutics, Inc. insiders sold a net $26.2K of stock across 93 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Tingley Whittemore
Chief Medical Officer
SELL
2026-08-17
1,637.0
$1.2K
Tingley Whittemore
Chief Medical Officer
SELL
2026-08-17
1,871.0
$1.3K
Tingley Whittemore
Chief Medical Officer
SELL
2026-08-17
2,279.0
$1.6K
Ali Faraz
Chief Executive Officer
SELL
2026-08-17
5,837.0
$4.1K
Ali Faraz
Chief Executive Officer
SELL
2026-08-17
3,969.0
$2.8K
93 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 88 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
VANGUARD CAPITAL MANAGEMENT LLC
7,101,263.0 sh
$5.2M
MILLENNIUM MANAGEMENT LLC
6,429,648.0 sh
$4.8M
CITADEL ADVISORS LLC
4,566,774.0 sh
$3.4M
RENAISSANCE TECHNOLOGIES LLC
4,281,100.0 sh
$3.2M
BlackRock, Inc.
4,008,719.0 sh
$3.0M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Faraz Ali
FILED 2026-08-17
$15.8K
Whittemore Tingley
FILED 2026-08-17
$5.3K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Ultra-Small Company Market Fund
$121.2K POSITION · AS OF 2026-03-31
0.1%
iShares Biotechnology ETF
$830.9K POSITION · AS OF 2026-03-31
0.0%
Invesco Nasdaq Biotechnology ETF
$5.2K POSITION · AS OF 2026-02-28
0.0%
ProShares Ultra Nasdaq Biotechnology
$4.3K POSITION · AS OF 2026-02-28
0.0%
Invesco RAFI US 1500 Small-Mid ETF
$86.5K POSITION · AS OF 2026-04-30
0.0%
Victory Extended Market Index Fund
$12.8K POSITION · AS OF 2026-04-30
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 4 registered trials, 4 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
1 ACTIVE
2
Not applicable
2 ACTIVE
1
Multi-phase
1 ACTIVE
What changed recently
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopat
2026-09-03 · Recruiting → Active Not Recruiting
—
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
OPERATING INCOME$-93.3M$-115.9M$-131.2M$-125.6M
NET INCOME$-90.6M$-111.1M$-124.1M$-123.7M
EPS (DILUTED)-0.59-1.31-1.68-2.76
OPERATING CASH FLOW$-68.3M$-90.5M$-102.1M$-104.4M
CASH$100.5M$4.3M$45.7M$95.3M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →